USPI booked half its 2026 deal budget in Q1 — and the math caps what sellers can ask

Tenet’s ambulatory arm spent $125 million in the first quarter of 2026 to acquire seven surgery centers — half of its full-year deal budget, committed by March 31. On the company’s Q1 2026 earnings call, CEO Saum Sutaria said United Surgical Partners International “had a particularly strong start to the year, investing $125 million in the first quarter to acquire seven ASCs,” adding that the company “commenced patient care at three de novo centers” and that the spend “represents half of our targeted full-year spend already completed in the first quarter.”

That pace is the news. The framework behind it is the analysis.

Half the year, booked in a quarter

USPI runs to a public deployment plan: a “$250 million annual target for USPI M&A,” in Sutaria’s words on the call. Put the two numbers next to each other and the recompute is clean — $125 million against a $250 million target is exactly 50% of the year’s M&A and de novo budget deployed in the first three months.

Front-loading a capital-deployment budget tells you something the facility count alone does not. It means the pipeline is full enough, and the seller field deep enough, that USPI did not have to ration the year’s dollars to find centers worth buying. Sutaria framed the rest of 2026 as having “a number of future opportunities to support our $250 million annual target,” which is management’s way of saying the bid side is not supply-constrained.

For a separate read on USPI’s operating quarter — the volume and facility-add numbers — see our Q1 earnings split coverage. This piece is about the checkbook, not the case count.

The multiple spread Tenet showed investors

The reason the pace matters is the price USPI is willing to pay — and, more pointedly, the price it can choose not to pay. In its Q1 2026 investor slides, Tenet laid out the economics of its two growth levers side by side: acquisitions enter at “initial acquisition multiples of 8–10x improving to effective multiples of 5–7x within three years post-acquisition,” while “de novo facilities exceed targeted effective multiples of less than 2.0x.”

Read those two lines together and the build-vs-buy gap is stark. To acquire a center, USPI pays 8–10x at entry — call it roughly 9x as a midpoint — and works that down to an effective 5–7x over three years through its own volume and managed-care leverage. To build one from scratch, the company targets an effective multiple under 2.0x. The entry acquisition multiple is, on the midpoints, more than four times the de novo target; even the improved three-year acquisition multiple sits at roughly three times the cost of building.

That is not a knock on acquisitions. The 8–10x entry multiple buys an existing physician syndicate, a running case schedule, and in-network payer contracts that a de novo has to assemble over years. USPI keeps buying because a turnkey center with established surgeons is worth the premium. But the spread defines the buyer’s alternative — and the buyer’s alternative is what sets the ceiling on the seller’s ask.

Why the spread caps the seller’s ask

Here is the structural point for any independent ASC weighing an exit. The largest strategic buyer in the sector — USPI ended Q1 with 567 facility interests, 541 ASCs and 26 surgical hospitals per Tenet’s earnings release — does not need any single center. It can build instead of buy, and it has told investors its build economics beat its buy economics by a wide margin.

That optionality is a price ceiling. When an independent center’s owners push their ask above the range where USPI’s acquisition math still beats its de novo math, the rational strategic buyer walks and breaks ground nearby instead. The de novo multiple of under 2.0x is the buyer’s outside option; the 8–10x entry multiple is the most a disciplined strategic will pay before building becomes the better deal. Sellers price into that band whether they name it or not.

A modeled illustration (illustrative, not a forecast). To size the gap in dollars, hold one assumption fixed: a center generating $5 million of annual EBITDA. Assumptions: USPI’s stated 8–10x entry range and its stated de novo target of under 2.0x effective; no synergy or ramp adjustments. At a 9x entry multiple, acquiring that center costs about $45 million. Building comparable EBITDA at an effective 2.0x would imply roughly $10 million of invested capital — under a quarter of the acquisition price. The point is not the exact dollar figure, which depends on a center’s actual EBITDA, ramp curve, and local certificate-of-need rules; the point is the order of magnitude. When building costs a quarter of buying, the buyer holds the leverage in every negotiation that starts above the de novo line.

What the platform was built on

The deployment discipline is not new — it is how USPI got this big. Tenet’s slides note the platform “expanded from 267 facilities at year-end 2017 to 567 facilities as of March 31, 2026.” That is 300 net facility interests added over roughly eight years, against a deployment cadence that now sits at about $250 million a year split between M&A and de novo development. The 567 figure reconciles with the earnings release’s 541 ASCs plus 26 surgical hospitals.

A platform that doubled its footprint on a steady, published budget is telling sellers something: the bid is patient and the bid is disciplined. USPI is not chasing a single trophy asset at any price; it is running a repeatable program where every acquisition is measured against the cost of building the same thing. For independent owners, that is the read — the largest buyer’s discipline is the market’s discipline, because its build option is always on the table.

Watch next

The number to watch in Tenet’s Q2 report, expected in July, is the spend pace: with half the annual target already committed, does USPI keep deploying at the front-loaded rate, or pace the back half against the $250 million baseline? A raised baseline would signal the pipeline is deepening; holding it would signal discipline. Either way, the de novo line — the under-2.0x build option — is the number that quietly sets the ceiling on what every independent seller in the sector can ask.